AdCD40L immunogene therapy for bladder carcinoma--the first phase I/IIa trial.

Abstract

PURPOSE Immunotherapy with Bacillus Calmette-Guerin (BCG) instillation is recommended for high-risk, non-muscle invasive bladder cancer. Bacillus Calmette-Guerin is not effective in advanced tumors, and better alternatives are warranted. Immunostimulating gene therapy with adenoviral vectors expressing CD40 ligand (AdCD40L) has shown efficacy in tumor models. CD40 ligand stimulates systemic immunity and may be effective in local and invasive human disease. EXPERIMENTAL DESIGN Patients with invasive bladder cancer scheduled for cystectomy or patients with T(a) tumors were enrolled in a phase I/IIa trial. Patients were treated with three cycles of intrabladder Clorpactin WCS-90 prewash, followed by AdCD40L instillation 1 week apart. Safety, gene transfer, immune effects, and antitumor responses were monitored. RESULTS All eight recruited patients were treated as scheduled, and therapy was well tolerated. The main adverse effect was transient local pain during prewash. Postoperatively, urinary tract infections and one case of late septicemia with elevated potassium were reported. No adverse events were ascribed to vector therapy. Gene transfer was detected in biopsies, and bladders were heavily infiltrated with T cells. The effector marker IFN-gamma increased in biopsies, whereas levels of circulating T regulatory cells were reduced. Histologic evaluation indicated that AdCD40L therapy reduced the load of malignant cells. CONCLUSIONS To our knowledge, this is the first report on immunogene therapy in bladder cancer and the first using AdCD40L in vivo. Local AdCD40L gene therapy was safe, boosted immune activation, and should be further evaluated as a single or an adjuvant therapy for urothelial malignancies.

DOI: 10.1158/1078-0432.CCR-10-0385

6 Figures and Tables

01002002011201220132014201520162017
Citations per Year

561 Citations

Semantic Scholar estimates that this publication has 561 citations based on the available data.

See our FAQ for additional information.

Cite this paper

@article{Malmstrm2010AdCD40LIT, title={AdCD40L immunogene therapy for bladder carcinoma--the first phase I/IIa trial.}, author={Per-Uno Malmstr{\"{o}m and A Loskog and Camilla A Lindqvist and Sara M. Mangsbo and Moa E Fransson and Alkwin Wanders and Truls G{\aa}rdmark and Thomas H. T{\"{o}tterman}, journal={Clinical cancer research : an official journal of the American Association for Cancer Research}, year={2010}, volume={16 12}, pages={3279-87} }